long intergenic non-protein coding RNA 1354Genealiases: []
Q-omics provides the consensus-scored LINC01354 profile across patient tissues and cancer cell-line models. LINC01354 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, LINC01354 is differentially expressed in 14, with the highest sampling consensus in THCA. Additionally, LINC01354 RNA expression shows 18,795 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight KIRC, THCA, and LUAD as cancer lineages where LINC01354 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC01354 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC01354 survival associations across molecular data types. LINC01354 RNA expression shows survival associations in the most cancer types (22). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC01354 RNA expression–survival associations across cancer types. High LINC01354 expression shows favorable associations in KIRC, UVM, HNSC, LUAD, ESCA and LIHC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for LINC01354 RNA expression.
This table summarizes LINC01354 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for LINC01354. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC01354 shows lower tumor expression in THCA, BLCA, KIRP, COAD, LUAD and UCEC. The THCA box plot shows higher LINC01354 RNA expression in normal versus tumor tissue (log2 FC = −1.592, t-test p < 0.001).
This table shows molecular features associated with LINC01354 in patient tissues and cancer cell lines. In patient samples, LINC01354 shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set.
